Ratings Medical System Network Co., Ltd.

Equities

4350

JP3920940008

Market Closed - Japan Exchange Other stock markets 07:00:00 26/04/2024 BST			5-day change	1st Jan Change
627 ^JPY	0.00%		-0.16%	-3.39%

02-19	Tranche Update on Medical System Network Co., Ltd.'s Equity Buyback Plan announced on February 16, 2024.	CI
02-19	Medical System Network Co., Ltd.'s Equity Buyback announced on February 16, 2024, has closed with 950,000 shares, representing 3.15% for ¥555.75 million.	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
The stock, which is currently worth 2024 to 0.34 times its sales, is clearly overvalued in comparison with peers.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.

Ratings chart - Surperformance

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MEDICAL SYSTEM NETWORK CO., LTD.	-3.39%	116M		-
WALGREENS BOOTS ALLIANCE, INC.	-32.21%	15.27B		B-
JD HEALTH INTERNATIONAL INC.	-31.97%	10.84B		B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-30.42%	6.06B		B
YIFENG PHARMACY CHAIN CO., LTD.	+8.14%	6.04B		C
MATSUKIYOCOCOKARA & CO.	-11.41%	5.86B		C+
NAHDI MEDICAL COMPANY	-1.17%	4.71B		D-
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+52.19%	4.29B	-	C
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-14.86%	3.33B		C-
WELCIA HOLDINGS CO., LTD.	-6.93%	3.01B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes